The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1288
Etravirine (Intelence) for HIV Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Etravirine (Intelence – Tibotec), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), has received fast-track FDA approval for use in combination therapy in treatment-experienced adults who have HIV-1 infection resistant to an NNRTI and other antiretroviral agents.1

MECHANISM OF ACTION — Etravirine binds directly to reverse transcriptase and blocks DNA polymerase by disrupting the enzyme’s catalytic site.

CLINICAL STUDIES — FDA approval of etravirine was based on interim 24-week results from two identical randomized, double-blind, placebo-controlled trials (DUET 1 and 2). The trials included a total of 1203 treatment-experienced patients with documented resistance to older NNRTIs — efavirenz (Sustiva), nevirapine (Viramune) or delavirdine (Rescriptor) — and to protease inhibitors (PIs). Significantly more ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Etravirine (Intelence) for HIV Infection
Article code: 1288c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian